Skip to content
DataLookout
Menu

NCT04846478

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

StatusActive, Not Recruiting
PhasePhase 1
Primary completion

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 19, 2026 Show 4 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 49 words
    • Secondary endpoint revised
    • Site details revised at 1 of 2 sites
  2. Minor Primary completion date changed from estimate of Mar 30, 2026 to Sep 25, 2025
    • Study completion date: Sep 30, 2026 to Dec 30, 2026
    v9
  3. Notable Primary completion date: Mar 30, 2025 to Mar 30, 2026
    • Study completion date: Sep 30, 2025 to Sep 30, 2026
    v8
  4. Minor Collaborators: 2 to 3v7
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 38 to confirmed 35
    • Site details revised at 2 of 2 sites
    v6
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Primary completion date: Mar 30, 2023 to Mar 30, 2025
    • Study completion date: Sep 30, 2023 to Sep 30, 2025
    v5
  2. Minor Primary completion date: Dec 31, 2022 to Mar 30, 2023
    • Study completion date: Jun 30, 2023 to Sep 30, 2023
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 1, 2021 to Jun 28, 2021
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Dose Limiting Toxicity (DLT)
Timeframe: Up to 28 days after treatment start (cycle 1)
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
Timeframe: Up to 2 years from treatment start

Secondary (1)

Overall Response Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)

Arms and interventions

Dose Escalation Talazoparib + TazemetostatExperimental

Standard 3+3 dose escalation will be followed, participants will initially receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications. During each 28 day study treatment cycle participants will take: * Talazoparib once daily. * Tazemetostat twice daily.

Dose Expansion Talazoparib + TazemetostatExperimental

Participants will receive talazoparib and tazemetostat at the safe dose identified in the first part (dose escalation) of the study. During each 28 day study treatment cycle participants will take: * Talazoparib once daily. * Tazemetostat twice daily.

Drugs: Talazoparib, Tazemetostat

Sites

2 sites in 1 country